REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving improved progression-free survival and time to pain progression. Anna Lacey spoke to Cora Sternberg about her group’s results from an international phase III trial, which were announced in Barcelona.